Tower Research Capital LLC TRC Reduces Position in Express Scripts Holding Co (ESRX)

Tower Research Capital LLC TRC lessened its position in shares of Express Scripts Holding Co (NASDAQ:ESRX) by 16.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,013 shares of the company’s stock after selling 6,549 shares during the period. Tower Research Capital LLC TRC’s holdings in Express Scripts were worth $3,136,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. American National Registered Investment Advisor Inc. lifted its position in shares of Express Scripts by 6.9% during the 3rd quarter. American National Registered Investment Advisor Inc. now owns 7,825 shares of the company’s stock worth $743,000 after buying an additional 505 shares during the last quarter. Bank of Stockton lifted its position in shares of Express Scripts by 5.2% during the 3rd quarter. Bank of Stockton now owns 11,821 shares of the company’s stock worth $1,123,000 after buying an additional 581 shares during the last quarter. Busey Trust CO lifted its position in shares of Express Scripts by 0.5% during the 3rd quarter. Busey Trust CO now owns 114,461 shares of the company’s stock worth $10,874,000 after buying an additional 617 shares during the last quarter. Strategic Advisors LLC lifted its position in shares of Express Scripts by 11.2% during the 3rd quarter. Strategic Advisors LLC now owns 6,201 shares of the company’s stock worth $589,000 after buying an additional 623 shares during the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of Express Scripts by 3.9% during the 3rd quarter. Bessemer Group Inc. now owns 18,940 shares of the company’s stock worth $1,800,000 after buying an additional 717 shares during the last quarter. Institutional investors own 83.15% of the company’s stock.

Shares of Express Scripts stock opened at $101.47 on Friday. The firm has a market cap of $57.07 billion, a price-to-earnings ratio of 14.29, a PEG ratio of 1.27 and a beta of 0.89. The company has a quick ratio of 0.65, a current ratio of 0.77 and a debt-to-equity ratio of 0.63. Express Scripts Holding Co has a one year low of $61.30 and a one year high of $101.71.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $2.43 EPS for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.01. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. The company had revenue of $25.56 billion during the quarter, compared to the consensus estimate of $25.11 billion. During the same quarter in the prior year, the firm earned $2.51 EPS. Express Scripts’s quarterly revenue was up 3.6% on a year-over-year basis. On average, equities research analysts forecast that Express Scripts Holding Co will post 9.08 earnings per share for the current year.

In other news, Director Mahon Thomas P. Mac sold 5,234 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $99.50, for a total transaction of $520,783.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.79% of the company’s stock.

ESRX has been the subject of several recent analyst reports. Royal Bank of Canada boosted their price objective on shares of Express Scripts to $94.00 and gave the stock an “outperform” rating in a research report on Monday, August 27th. ValuEngine upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a research report on Monday, September 17th. BidaskClub upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. Credit Suisse Group downgraded shares of Express Scripts from an “outperform” rating to a “neutral” rating and boosted their price objective for the stock from $90.00 to $96.50 in a research report on Tuesday, September 18th. Finally, Maxim Group restated a “hold” rating on shares of Express Scripts in a research report on Thursday, November 1st. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $90.60.

WARNING: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2018/12/01/tower-research-capital-llc-trc-reduces-position-in-express-scripts-holding-co-esrx.html.

Express Scripts Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Featured Story: Risk Tolerance

Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit